XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 6 Months Ended
Oct. 01, 2016
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
SEGMENT AND ENTERPRISE-WIDE INFORMATION
We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the plasma business. We aggregate components within an operating segment that have similar economic characteristics.
The Company’s reportable segments are as follows:
•
Japan
•
Europe, Middle East and Africa (collectively “EMEA”)
•
North America Plasma
•
All Other
The Company has aggregated the following two operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin:
•
Americas Blood Center and Hospital
•
Asia - Pacific
In periods prior to the fourth quarter of fiscal 2016, we believed a single reportable segment was consistent with its basic organizational structure and believed aggregation was consistent with its primary basis for decision making. As a result, prior year segment information has been restated to conform with the current reportable segments.
During the first quarter of fiscal 2017, management reorganized its operating segments such that certain components of All Other are now reported as components of EMEA. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2017. These changes did not have an impact on our ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.
Management measures and evaluates the operating segments based on operating margin. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and asset impairments. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income on a constant currency basis, therefore segment information is presented on a constant currency basis.
Selected information by business segment is presented below:
 
Three Months Ended
 
Six Months Ended
(In thousands)
October 1,
2016
 
September 26,
2015
 
October 1,
2016
 
September 26,
2015
Net revenues
 
 
 
 
 
 
 
Japan
$
18,991

 
$
19,908

 
$
33,557

 
$
37,503

EMEA
45,933

 
48,198

 
91,674

 
97,009

North America Plasma
78,292

 
68,606

 
151,767

 
133,049

All Other
78,411

 
82,780

 
156,431

 
162,999

Net revenues (constant currency)
221,627

 
219,492

 
433,429

 
430,560

Effect of exchange rates
(1,374
)
 
201

 
(3,220
)
 
2,546

Net revenues (reported)
$
220,253

 
$
219,693

 
$
430,209

 
$
433,106

 
Three Months Ended
 
Six Months Ended
(In thousands)
October 1,
2016
 
September 26,
2015
 
October 1,
2016
 
September 26,
2015
Segment operating income
 
 
 
 
 
 
 
Japan
$
8,883

 
$
8,948

 
$
15,004

 
$
16,630

EMEA
10,702

 
11,486

 
20,750

 
22,012

North America Plasma
28,272

 
27,309

 
55,549

 
53,464

All Other
30,329

 
29,839

 
55,965

 
58,474

Segment operating income (constant currency)
78,186

 
77,582

 
147,268

 
150,580

Corporate operating expenses (constant currency)
(45,416
)
 
(46,275
)
 
(93,867
)
 
(95,526
)
Non-GAAP operating income (constant currency)
32,770

 
31,307

 
53,401

 
55,054

Effect of exchange rates
667

 
1,802

 
(639
)
 
3,882

Non-GAAP operating income (reported)
33,437

 
33,109

 
52,762

 
58,936

Unallocated amounts
 
 
 
 
 
 
 
Restructuring and turnaround costs
1,637

 
6,531

 
20,453

 
21,347

Deal amortization
7,006

 
7,399

 
14,081

 
14,804

Asset impairments
—

 
—

 
1,315

 
—

Operating income
$
24,794

 
$
19,179

 
$
16,913

 
$
22,785



In connection with the global strategic review of our business portfolio, we organized our current products into four franchises for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these franchises.
Net revenues by franchise are as follows:
 
 
Three Months Ended
Six Months Ended
(In thousands)
 
October 1,
2016
 
September 26,
2015
 
October 1, 2016
 
September 26, 2015
Plasma
 
$
103,564

 
$
93,036

 
$
201,213

 
$
181,563

Blood Center
 
74,270

 
84,235

 
145,213

 
167,318

Cell Processing
 
25,955

 
28,105

 
52,031

 
55,918

Hemostasis Management
 
16,464

 
14,317

 
31,752

 
28,307

Net revenues
 
$
220,253

 
$
219,693

 
$
430,209

 
$
433,106

Net revenues generated in our principle operating regions on a reported basis are as follows:
 
Three Months Ended
 
Six Months Ended
(In thousands)
October 1,
2016
 
September 26,
2015
 
October 1,
2016
 
September 26,
2015
United States
$
130,843

 
$
127,031

 
$
256,543

 
$
247,726

Japan
21,666

 
16,190

 
36,630

 
30,924

Europe
37,606

 
47,869

 
77,973

 
98,157

Asia
28,384

 
26,603

 
55,376

 
52,123

Other
1,754

 
2,000

 
3,687

 
4,176

Net revenues
$
220,253

 
$
219,693

 
$
430,209

 
$
433,106